# Botulinum Toxin Injection to Treat Bruxism in a Child: A Case Report and Technique Description

**Authors:** Franco Ignáccio Mallaguti, José Geraldo Malaguti, Otacilio de Paula Rodrigues Júnior

PMC · DOI: 10.7759/cureus.103108 · Cureus · 2026-02-06

## TL;DR

This case report shows that botulinum toxin injections can safely and effectively treat bruxism in a healthy child.

## Contribution

This is the first known report of botulinum toxin use for bruxism in a healthy pediatric patient.

## Key findings

- Symptoms improved within a day and lasted about two months.
- No adverse reactions were observed in the treated child.
- BTX-A may be a safe alternative for managing muscle hyperactivity in children.

## Abstract

Managing sleep bruxism (SB) in children remains a clinical challenge due to the limited evidence-based treatment options for muscle hyperactivity in this population. This case report describes the successful use of botulinum toxin type A (BTX-A) in managing SB in an otherwise healthy eight-year-old girl. The patient received 10 units of BTX-A in each masseter muscle, administered at two points per side using anatomical landmarks and muscle palpation to guide injection. Symptom resolution was reported as early as the day after treatment, with effects lasting approximately two months and no adverse reactions observed. This is the first known report of BTX-A being used to treat bruxism in a healthy pediatric patient. The findings suggest that botulinum toxin may be a safe and effective alternative for managing muscle hyperactivity in children. Further research is needed to establish optimal dosing protocols and long-term safety.

## Linked entities

- **Diseases:** bruxism (MONDO:0002443)

## Full-text entities

- **Genes:** SNAP25 (synaptosome associated protein 25) [NCBI Gene 6616] {aka CMS18, DEE117, RIC-4, RIC4, SEC9, SNAP}
- **Diseases:** allergies (MESH:D004342), masticatory muscle tenderness (MESH:D063806), muscle hyperactivity (MESH:D009135), asymmetry (MESH:D005146), SB (MESH:D020186), Rett syndrome (MESH:D015518), brain injuries (MESH:D001930), masticatory muscle hyperactivity (MESH:C563600), dentin hypersensitivity (MESH:D003807), AB (MESH:D002012), toxicity (MESH:D064420), psychological disorders (MESH:D000067073), fatigue (MESH:D005221), restricted mouth opening (MESH:D009059), temporomandibular disorders (MESH:D013705), muscular hyperactivity (MESH:D006948), orofacial pain (MESH:D005157), dental wear (MESH:D057085), autism spectrum disorder (MESH:D000067877), dental pain (MESH:D010146), tooth surface loss (MESH:D016388), headaches (MESH:D006261), periodontal problems (MESH:D010518), tension (MESH:D018781), autism (MESH:D001321), clicks (MESH:D008945)
- **Chemicals:** lidocaine (MESH:D008012), Hydroxyzine (MESH:D006919), saline (MESH:D012965)
- **Species:** Melissa officinalis (common balm, species) [taxon 39338], Homo sapiens (human, species) [taxon 9606], Phytolacca americana (American pokeweed, species) [taxon 3527], Clostridium botulinum (species) [taxon 1491]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967495/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967495/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967495/full.md

---
Source: https://tomesphere.com/paper/PMC12967495